According to a report by Bloomberg on August 31, a senior official from the U.S. Department of Health and Human Services (HHS) has called for the relaxation of restrictions on marijuana in a letter to the Drug Enforcement Administration (DEA). The official has recommended reclassifying marijuana as a Schedule III substance, and the DEA is initiating a review of the drug.
Assistant Secretary of Health and Human Services, Rachel Levine, wrote a letter to DEA Administrator, Anne Milgram, suggesting the reclassification of cannabis as a Schedule III substance. Currently classified as a Schedule I controlled substance, alongside highly dangerous substances like heroin and hallucinogens.
According to a report by US cable news network CNN, a spokesperson for the Drug Enforcement Administration (DEA) has confirmed in an email statement to CNN that the agency has received a letter from the Department of Health and Human Services (HHS) and is now launching a review.
Statement claims: "We can confirm that the DEA has received a letter from HHS, providing the investigation findings and recommendations regarding marijuana arrangements, as requested by President Biden for review. As part of this process, HHS conducted scientific and medical assessments to be considered by the DEA."sdxz
The statement indicates that the DEA possesses the ultimate authority to schedule or reschedule drugs under the Controlled Substances Act. The DEA will now initiate a review.
According to data from the National State Legislatures Conference, 23 states have legalized adult-use marijuana, while 38 states allow marijuana products for medical purposes. Since Colorado first began selling adult-use marijuana in 2014, the marijuana industry has evolved into a multi-billion dollar market, attracting the attention of multinational corporations in sectors such as alcohol, agriculture, pharmaceuticals, and tobacco.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
